바이오인

The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients

The biopharmaceutical pipeline of new medicines contains a stunning range of innovative new treatment approaches that have the potential to save lives and improve patient health. A new report by Analysis Group, “Innovation in the Biopharmaceutical Pipeline: A Multi-Dimensional View,” examines the pipeline from several different angles to capture the breadth and focus of ongoing research and to describe the array of potential new treatments and cures for patients. Across several measures of “innovativeness,” the report found:

? Many novel scientific strategies are opening up new possibilities for fighting disease.
? Potential first-in-class medicines make up 70% of the pipeline.
? Nearly three times as many drugs for rare diseases and conditions are in the pipeline compared with a decade ago.
? Researchers are actively studying diseases and conditions with no recent approvals such as ALS, ovarian cancer, and septic shock.
? Personalized medicines are a growing proportion of the pipeline.

The analysis found that more than 5,000 potential new medicines
? which may become available to U.S. patients ? are in the pipeline globally ? in large part funded by the more than $500 billion invested in research and development (R&D) since 2000 by PhRMA member companies. These promising candidates build on the more than 300  medicines that have been approved by the FDA in the last decade.

........(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.